Eisai Signs a Research Collaboration with BioArctic to Characterize BAN2401's Mechanism of Action
Shots:
- Eisai and BioArctic collaborate to further characterize the MOA of BAN2401. Earlier in 2005- the companies partnered for the therapy targeting Alzheimer's disease and later in 2007- BioArctic licensed BAN2401 to Eisai
- Under the research collaboration- BioArctic will receive $3.89M from Eisai and is expected to continue the collaboration through the end of Jun’2021
- BAN2401 is an investigational mAb selectively targeting toxic amyloid-beta aggregates in the brain- currently being evaluated in P-III CLARITY study in patients with early Alzheimer´s disease with its anticipated results in 2020
Click here to read full press release/ article | Ref: BioArctic | Image: Eisai
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
